Friday, February 22, 2013

Drug Discovery@nature.com 22 February 2013

Drug Discovery

TABLE OF CONTENTS

22 February 2013

News
Analysis
Research Highlights
Research & Reviews
Careers


Nature Reviews Drug Discovery is on Twitter

Advertisement
Molecular Systems Biology - New Reviews Series

Reading and writing omes
Church doi:10.1038/msb.2012.75

Genome-scale engineering for systems and synthetic biology
Esvelt & Wang doi:10.1038/msb.2012.66

High-throughput sequencing for biology and medicine
Soon, Hariharan & Snyder doi:10.1038/msb.2012.61

Read free content here
 

News

Top

Gene sequencing leaves the laboratory
doi:10.1038/494290a
Maturing technology speeds medical diagnoses.
Full Text

Malaria drug made in yeast causes market ferment
doi:10.1038/494160a
Synthetic biology delivers combination therapies into an uncertain market.
Full Text

Data barriers limit genetic diagnosis
doi:10.1038/494156a
Tools for data-sharing promise to improve chances of connecting mutations with symptoms of rare diseases.
Full Text

The clot thickens for long-lasting drugs that stop hemophilia short
doi:10.1038/nm0213-121
Several long-lasting biologics for hemophila are moving towards the market.
Full Text

Analysis

Top

Cancer target selection pressure
doi:10.1038/scibx.2013.128
An Institute of Cancer Research team has developed a computational algorithm that hones in on cancer targets with the desired mix of biological validation and druggability.
Full Text

Smoking cessation drugs market
doi:10.1038/nrd3914
This analysis looks at smoking cessation therapies currently in development, including the novel approach of vaccinating smokers against nicotine.
Full Text

Research Highlights

Top

Antibacterial drugs: New antibiotics on the horizon?
doi:10.1038/nrd3940
Two recent papers report novel strategies for combating the prevalent bacterial pathogen Staphylococcus aureus.
Full Text

Neurodegenerative disease: Targeting pre-existing plaques in AD
doi:10.1038/nrd3939
Researchers have developed a plaque-specific monoclonal antibody that can clear existing plaques without the side effects seen with other anti-amyloid-β therapeutics in development.
Full Text

Anticancer drugs: Assault on MALT1
doi:10.1038/nrd3942
Two new studies have identified small-molecule inhibitors of MALT1 that show anticancer activity in vitro and in vivo.
Full Text

Research & Reviews

Top

Targeting eosinophils in allergy, inflammation and beyond
doi:10.1038/nrd3838
The authors describe recent advances in the development of the first generation of therapies that target eosinophils, as well as emerging strategies.
Full Text

Advances in targeting cell surface signalling molecules for immune modulation
doi:10.1038/nrd3877
This review discusses immunomodulatory signalling pathways that provide targets for therapeutic intervention and the current state of drug development in the field.
Full Text

Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production
doi:10.1038/nbt.2458
Researchers present a systems-based method to tune ROS production in bacteria and demonstrate that increased microbial ROS production can potentiate killing by oxidants and antibiotics.
Full Text

Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance
doi:10.1038/nm.3056
As expression of this transcriptional regulator is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia.
Full Text

Drug Discovery
JOBS of the week
Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
Postdoctoral Research Scientist in Experimental Fluid Dynamics / Transport Phenomena
Attinger's lab - Iowa State University
Research Associate / Sr Research Associate - Cancer Immunotherapy
Genentech
Research Associate
Imperial College London
Medicinal Chemist (IMI European Lead Factory)
University of Dundee, College of Life Sciences
More Science jobs from
Drug Discovery
EVENT
Tumor Imaging in Cancer Drug Development
04.30.13
Boston, US
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
Advertisement
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.

Recommend SciBX to your library today.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: